Genmab A/S (GNMSF)

Market Cap	18.32B
Revenue (ttm)	3.65B
Net Income (ttm)	1.37B
Shares Out	n/a
EPS (ttm)	21.62
PE Ratio	13.36
Forward PE	18.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	4,518
Open	297.22
Previous Close	297.22
Day's Range	297.22 - 303.50
52-Week Range	170.00 - 336.45
Beta	0.82
RSI	45.89
Earnings Date	Nov 6, 2025

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 2,682
• Stock Exchange: OTCMKTS
• Ticker Symbol: GNMSF

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.